A month has gone by since the last earnings report for Hims & Hers Health, Inc. (HIMS) . Shares have added about 38% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Hims & Hers Health due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.Hims & Hers Q4 Earnings Beat Estimates ...

Key Takeaways HIMS operates a consumer-first platform, integrating telehealth, prescriptions and pharmacy fulfillment.HIMS expands in diagnostics with Labs and early cancer detection, plus specialty care like GLP-1 therapies.Hims & Hers scales globally via acquisitions like Eucalyptus and expansion into Canada and Europe.Renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS) is fundamentally built as a consumer-first digital health platform that uses technology to reconfigure how care is acc ...

Healthpeak (DOC) is being valued as a mix between medical offices and labs. By property value, however, it is fully 25% senior housing. Senior housing values have dramatically expanded in recent periods, yet this value has not shown up in DOC’s stock price. In response, DOC is spinning off its senior housing into Janus Living (JAN) which, upon its IPO, should force the market to directly value its senior housing assets. I believe the IPO will reveal the true value of DOC’s senior housing as $4.25B rather th ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is developing a technology-driven healthcare platform aimed at making personalized care more accessible and convenient for consumers [1] - The company integrates digital infrastructure, telehealth capabilities, and an ecosystem for end-to-end care, moving towards individualized, consumer-centric healthcare experiences [1] Group 1: Recent Developments - Hims & Hers has launched Labs, a data-driven testing service that provides health insights and doctor-developed action plans for proactive healthcare [2][7] - The company has expanded its specialty offerings to include menopause and perimenopause care for women, as well as enhanced testosterone treatments for men, all designed for personalized treatment plans [2][7] - A multi-cancer early detection test has been introduced, screening for signals across more than 50 cancer types, emphasizing proactive health management [3] Group 2: Expansion and Innovation - Hims & Hers is scaling its platform through strategic acquisitions and international expansion, entering markets such as Canada and Europe [3] - The company is focused on enhancing the accessibility of personalized care through its expanding digital health ecosystem [3] Group 3: Financial Performance - Hims & Hers shares have decreased by 52.2% over the past year, underperforming the industry average decline of 27.6% [6] - The Zacks Consensus Estimate for HIMS' earnings per share in 2026 suggests flat performance compared to 2025 [8] - HIMS' forward 12-month price-to-sales ratio is 1.3X, significantly lower than the industry's average of 3.6X and its five-year median of 2.7X, indicating potential undervaluation [10]

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]

Core Insights - Digital healthcare is evolving with distinct approaches represented by Hims & Hers Health, Inc. (HIMS) and American Well Corporation (AMWL), focusing on consumer-first and enterprise platforms respectively [1][2] Company Overview - HIMS operates a subscription-based platform connecting consumers to healthcare providers for telehealth consultations and wellness support, while AMWL provides technology infrastructure for health systems and plans to deliver hybrid care [1][2] - HIMS is expanding into various health categories including weight management, menopause, and testing, while AMWL is refocusing on enterprise clients and targeting positive cash flow by 2026 [6][10] Stock Performance & Valuation - HIMS has underperformed with a stock decline of 63.1% over the past year, while AMWL's stock declined by 46.6% [3] - HIMS has a forward price-to-sales (P/S) ratio of 1.3X, below its five-year median of 2.7X, while AMWL's forward P/S is at 0.4X, below its five-year median of 1.6X [5] Growth Strategies - HIMS is investing in AI, diagnostics, and acquisitions to enhance its platform and expand internationally, with recent agreements to acquire companies in Australia, Japan, Germany, and the U.K. [8][9] - AMWL has streamlined operations and focused on its core platform, strengthening recurring revenue and aligning with demand for consolidated digital health infrastructure [10][12] Financial Projections - HIMS' earnings per share (EPS) for 2026 is projected to remain flat year-over-year, while AMWL's loss per share is expected to improve by 46.8% from 2025 [14][16] - The average price target for HIMS is $25.54, indicating a potential increase of 65.2%, while AMWL's average price target is $6.25, suggesting a 15.3% increase [18][19] Investment Outlook - HIMS is viewed as better positioned for long-term growth despite recent underperformance, with a focus on expanding its consumer platform and enhancing engagement [21][22] - AMWL is advancing its enterprise strategy but faces revenue decline, making HIMS a more compelling opportunity for investors seeking telehealth exposure [22][23]

Core Insights - Hims & Hers Health, Inc. reported a fourth-quarter 2025 EPS of 7 cents, down from 11 cents year-over-year, but exceeding the Zacks Consensus Estimate of 2 cents [1] - Full-year EPS was 51 cents, reflecting a 3.8% decrease from the previous year, yet surpassing the Zacks Consensus Estimate by 6.3% [1] Revenue Performance - Fourth-quarter revenues reached $617.8 million, a 28.4% increase year-over-year, but slightly below the Zacks Consensus Estimate by 0.2% [2] - Full-year revenues totaled $2.35 billion, marking a 58.9% improvement from the prior year and aligning with the Zacks Consensus Estimate [2] Geographical Results - U.S. revenues in Q4 2025 improved by 16.8% year-over-year to $554.1 million, while revenues from the Rest of the World surged to $63.7 million from $6.9 million in the previous year [3] Segment Analysis - Online Revenues for the quarter were $609.1 million, reflecting a 29.4% year-over-year increase, with total subscribers reaching 2.5 million, up 12.7% [4] - Wholesale Revenues were reported at $8.7 million, down 16.1% year-over-year [6] Margin and Expense Analysis - Gross profit increased by 20.3% year-over-year to $444.4 million, but gross margin contracted by 487 basis points to 71.9% [7] - Operating expenses rose 24% year-over-year to $435.2 million, leading to an operating profit of $9.2 million, a 50.6% decline from the previous year [8] Financial Position - Hims & Hers ended 2025 with cash and cash equivalents of $577.5 million, up from $300.3 million at the end of 2024 [9] - Cumulative net cash from operating activities was $300 million, compared to $251.1 million a year prior [9] Future Outlook - For Q1 2026, the company projects revenues between $600 million and $625 million, indicating a year-over-year growth of 2%-7% [10] - Full-year revenue guidance for 2026 is set between $2.7 billion and $2.9 billion, representing a growth of 15%-24% from 2025 levels [11] Strategic Developments - Hims & Hers has entered an agreement to acquire Eucalyptus, expanding its reach in consumer healthcare across multiple countries [13] - Recent product launches, including a cancer screening blood test and health assessment tools, are expected to enhance subscriber engagement and revenue [14] Market Reaction - Shares of Hims & Hers fell nearly 6.3% in pre-market trading following the earnings report [2] - The company currently holds a Zacks Rank of 4 (Sell) [16]

Group 1: Marketing and Brand Investment - Management attributes marketing leverage gains to long-term brand investment, allowing for a 7-point year-over-year improvement in marketing as a percentage of revenue [1] Group 2: Strategic Investments and Revenue Growth - Strategic verticalization through $300 million in facility investments has enabled the company to lower costs and deliver custom pharmaceutical-supplement formulas at scale [2] - The weight loss offering reached a $100 million revenue run rate in less than seven months, excluding compounded GLP-1s, demonstrating strong demand for non-injectable metabolic treatments [2] Group 3: Performance Metrics and Future Guidance - Performance was driven by a 65% adoption rate of personalized treatments among 2.5 million subscribers, which increased monthly revenue per subscriber by 11% year-over-year [3] - Management is transitioning the platform from reactive specialty care to a proactive, data-driven longevity model centered on diagnostics and personalized interventions [3] - 2026 guidance assumes a $65 million revenue headwind in Q1 due to shifting shipping cadences for weight loss products, characterized as a timing issue rather than a demand decline [3] - The company expects newer specialties including testosterone support, menopause care, and Labs to each eclipse $100 million in annual revenue in the near future [3] - International operations are projected to break even within 12 to 18 months, focusing on growth over immediate margin expansion in new markets like Australia and Japan [3] - Management anticipates that AI-driven conversational support and proactive messaging will improve customer commitment, citing a 50% increase in weight logging frequency during early deployments [3] - The 2030 target of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA remains the North Star, supported by the stacking of diverse growth engines across geographies [3]

Core Insights - Hims & Hers Health, Inc. (HIMS) is establishing itself as a leading digital health platform focused on personalized, technology-enabled care, expanding its offerings across various life stages and health conditions [1][8] - The company has launched new specialties in women's health, including menopause and perimenopause, and in men's health with a low testosterone category, providing tailored treatment plans [1][8] - Hims & Hers is advancing into proactive, data-driven care with the introduction of Labs for comprehensive health monitoring and a multi-cancer early detection blood test [2][8] Company Developments - Hims & Hers has introduced a dedicated menopause and perimenopause specialty on the Hers platform, along with a low testosterone category on the HIMS platform, enhancing its service offerings [1][8] - The launch of Labs allows customers to monitor key health markers over time, supported by provider-guided action plans, and includes a multi-cancer early detection blood test for over 50 cancer types [2][8] - The company is making strategic investments in AI, diagnostics, and global expansion to create a connected healthcare platform that prioritizes personalized, preventive care [2][8] Financial Performance - Hims & Hers shares have decreased by 67.9% over the past year, underperforming the industry average decline of 32.8% [7] - The Zacks Consensus Estimate for HIMS' earnings per share in 2025 indicates a significant improvement of 77.8% compared to 2024 [9] - HIMS' forward 12-month price-to-sales ratio is 1.3X, which is lower than the industry average of 3.7X and its five-year median of 2.7X, reflecting a Value Score of C [11]

Core Insights - Hims & Hers Health, Inc. (HIMS) is set to report its fourth-quarter 2025 results on February 23, with expectations of a revenue increase of 28.7% year-over-year, but a significant drop in earnings per share (EPS) by 81.8% compared to the prior year [1][6][21] Group 1: Performance Factors - The company's fourth-quarter results are anticipated to reflect ongoing momentum in its personalized, multi-specialty platform strategy, including expansions into men's health and menopause care, which broaden its market and enhance customer engagement [3][4] - International expansion efforts, such as entering Canada and launching a Weight Loss Programme in the U.K., are expected to contribute to growth by capturing additional demand outside the U.S. [4] - The introduction of Labs for biomarker testing and personalized action plans is likely to improve cross-selling opportunities and customer retention [4] Group 2: Financial Estimates - The Zacks Consensus Estimate for revenues in Q4 2025 is $619.2 million, representing a 28.7% increase from the previous year [6] - The consensus estimate for EPS is 2 cents, indicating a significant decline of 81.8% from the prior year's figure [6] Group 3: Cost and Legal Challenges - Rising operating expenses due to aggressive marketing, technology investments, and infrastructure development may negatively impact fourth-quarter results [5] - Ongoing legal scrutiny regarding compounded semaglutide products, including litigation from Novo Nordisk, could create uncertainty and pressure growth in the weight-loss segment [5] Group 4: Stock Performance and Valuation - Hims & Hers shares have declined by 52.9% over the past three months, underperforming both the Medical Info Systems sector and the S&P 500 [10] - The company's forward price-to-sales (P/S) ratio is 1.3X, which is below the industry average of 3.7X and its five-year median of 2.7X, indicating a potential undervaluation relative to expected sales growth [15][17] Group 5: Long-Term Strategy - Hims & Hers' long-term investment strategy focuses on capital allocation and platform expansion, supported by an $870 million convertible senior notes offering that enhances financial flexibility for global expansion and strategic acquisitions [18] - The appointment of an AI veteran as CTO indicates a strategic shift towards building an AI-powered care platform, aimed at improving diagnostic precision and treatment personalization [19] - The combination of disciplined capital deployment, technology-driven infrastructure, and international expansion is expected to provide sustained revenue growth and margin expansion over the long term [19][20]